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Sabrina Seguin6 and Olivier Mimoz6,7*Abstract
Background: Catheter-related infection is the third cause of infections in intensive care units (ICU), increasing
the length of stay in ICU and hospital, mortality, and costs. Skin antisepsis is one of the most prevalent
preventive measures. In this respect, it would appear preferable to recommend the use of alcoholic povidone
iodine or chlorhexidine rather than aqueous povidone iodine. However, the data comparing chlorhexidine to
povidone-iodine, both of them in alcoholic solutions, remain limited. Moreover, the benefits of enhanced
cleaning prior to disinfection of skin that is not visibly soiled have yet to be confirmed in a randomized
study.
Methods: A prospective multicenter, 2×2 factorial, randomized-controlled, assessor-blind trial will be
conducted in 11 intensive care units in six French hospitals. All adult patients aged over 18 years requiring
the insertion of at least one peripheral arterial catheter and/or a non-tunneled central venous catheter and/or
a hemodialysis catheter and/or an arterial pulmonary catheter will be randomly assigned to have all their
catheters cared with one of four skin preparation strategies (2% chlorhexidine/70% isopropyl alcohol or 5%
povidone iodine/69% ethanol with or without prior skin scrubbing). At catheter removal, catheter tips will be
quantitatively cultured. Sets of aerobic and anaerobic blood cultures will be routinely obtained when a
patient has fever, hypothermia, or other indications. In case of suspected catheter-related infection the
patient’s form will be reviewed by an independent adjudication committee. We plan to enroll 2,400 patients
(4,800 catheters). The main objective is to demonstrate that use of 2% alcoholic chlorhexidine compared to
5% alcoholic povidone iodine in skin preparation lowers the rate of catheter-related infection. The second
endpoint is to demonstrate that enhanced skin cleaning prior to disinfection of skin that is not visibly soiled
does not reduce catheter colonization. Other outcomes include comparison of skin colonization at catheter
insertion site, comparison of catheter colonization and catheter-related bacteremia taking place during
implementation of the four strategies of skin preparation, and cutaneous tolerance, length of hospitalization,
mortality, and costs.
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Discussion: This study will help to update recommendations on the choice of an antiseptic agent to use in
skin preparation prior to insertion of a vascular catheter and, by extension, of an epidural catheter and it will
likewise help to update recommendations on the usefulness of skin scrubbing prior to disinfection when the
skin is not visibly soiled.
Trial registration: Clinicaltrials.gov number NCT01629550
Keywords: Central venous catheter, Arterial catheter, Colonization, Bacteremia, Severely ill patientBackground
Catheter-related infections represent the third cause of
infections in intensive care units (ICUs) after pneumonia
and complicated intra-abdominal infections [1]. These
infections increase the length of ICU and hospital stay,
mortality, and costs. Additional costs as high as $30,000
per survivor have been reported, including 1 extra week in
the ICU and 2 to 3 additional weeks in the hospital [2].
Attributable mortality rates range from 0 to 35%, depend-
ing on the degree of control for severity of illness [2].
The physiopathology of catheter infection is now more
clearly understood [2]. For short-term catheters such as
those inserted in ICUs, catheter tip colonization arises
during catheter insertion or, less frequently, by migration
of skin organisms from the insertion site into the cuta-
neous catheter tract during catheter maintenance. The
density of micro-organisms at catheter insertion site is
therefore a major risk factor for short-term catheter-
related infection, while skin antisepsis is one of the most
effective preventive measures.
Povidone iodine and chlorhexidine are the two most
commonly used antiseptic agents, both of them being
available as aqueous and alcoholic formulations. Their
respective efficacy in preventing catheter colonization
and bloodstream infections has been compared in nu-
merous studies. One meta-analysis including eight ran-
domized trials and 4,143 short-term catheters, published
in 2002, found that chlorhexidine solutions either in
aqueous or alcoholic formulations significantly reduced
catheter-related bloodstream infections by approximately
50% (RR, 0.51 (95% CI, 0.27-0.97)) compared to 10% for
aqueous povidone iodine [3]. These findings were subse-
quently confirmed in other trials [4-6], leading in many
countries, the USA [7], England [8], and France [9], to
cessation of the recommendation of aqueous povidone
iodine in catheter care. The superiority of chlorhexidine
has been linked by some authors to a synergistic effect
with alcohol, which has also been demonstrated with
povidone iodine. Compared to aqueous 10% povidone-
iodine, a double application of 5% povidone iodine in
69% ethanol reduced the incidence of catheter coloni-
zation (RR, 0.38 (95% CI, 0.22-0.65)) and catheter-
related infection (RR, 0.34 (95% CI, 0.13-0.91)) in arandomized unit-crossover study that included 223
central venous catheters [10]. No significant effect was
observed on bloodstream infections, but the study was
underpowered to explore this issue.
Two French trials have directly compared alcoholic
formulations of chlorhexidine and povidone iodine. The
first one included 481 evaluable central venous catheters
inserted into jugular or subclavian veins [11]. Use of a
combination of 0.25% chlorhexidine gluconate, 0.025%
benzalkonium chloride, and 4% benzylic alcohol was as-
sociated with a reduction by half in the incidence of
catheter colonization (11.6% vs. 22.2% P= 0.002; inci-
dence density, 9.7 vs. 18.3 per 1,000 catheter-days). A
trend toward lower rates of catheter-related bloodstream
infection was likewise noted (1.7% vs. 4.2% P= 0.09; inci-
dence density, 1.4 vs. 3.4 per 1,000 catheter-days), not-
withstanding the fact that the study was not powered to
adequately explore this issue. However, lack of skin
scrubbing (which is strongly recommended in France)
prior to antiseptic administration, completion of the
study in a single unit, and use of a combination of three
compounds in the chlorhexidine arm all constituted ob-
stacles to generalization of these findings. The second
trial was a single-center before-after study comparing
the efficacy of the same antiseptics as in the previous
trial and included 435 central venous catheters in the
povidone iodine arm and 371 central venous catheters in
the chlorhexidine arm [12]. The switch from alcoholic
povidone iodine to the chlorhexidine-based antiseptic
solution was associated with a reduction in catheter
colonization (11.2 vs. 15.5 per 1,000 catheter days,
P=0.041) and a pronounced decline in catheter-related
bacteremia (1.4 vs. 3.0 per 1,000 catheter days, P=0.052).
Moreover, use of alcoholic povidone iodine was inde-
pendently associated with an increased risk of catheter
colonization or infection in multivariate cox model ana-
lysis (1.48, 95% CI, 1.01-2.15, P=0.043). This study none-
theless has several limitations, including its design, but it
succeeds in confirming the superiority of chlorhexidine-
based solutions over povidone iodine, even in alcoholic
formulations, in care of central venous catheters.
The superiority of chlorhexidine over povidone iodine
has been linked to quick bactericidal activity, poor
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present on skin, and long-term antimicrobial suppressive
activity. These findings have led the Centers for Disease
Control and Prevention (CDC) to include in their 2011
recommendations [7] the use of alcoholic chlorhexidine at
a concentration >0.5% as a first-line antiseptic in catheter
care. However, they pointed out that data comparing
chlorhexidine and povidone-iodine in alcoholic solutions
are limited and recommended the organization of a large-
scale study comparing alcoholic formulations of chlorhexi-
dine and povidone iodine.
In addition, skin scrubbing reduces bacterial load and
the amount of protein-rich biomaterials present on skin
and may thereby enhance the efficacy of antiseptics.
However, the benefits of enhanced skin cleaning prior to
disinfection of skin that is not visibly soiled have never
been confirmed in a randomized study. Its use, recom-
mended in only a few countries such as France, is based
on the results of a study showing a link between the
amount of skin colonization before antiseptic application
and catheter colonization [13]. These findings offer only
indirect evidence in favor of skin scrubbing before skin
antisepsis. The French Society of Hospital Hygiene
(SF2H) recommends the systematic skin scrubbing prior
to antisepsis while the CDC, on the other hand, indi-
cates that antiseptics could be directly applied on clean
skin [7].
The objectives of this study are to demonstrate in
adult ICU patients (1) the ability of 2% chlorhexidine/
70% isopropyl alcohol to decrease the rate of catheter-
related infection compared with the use of 5% povidone
iodine/69% ethanol and (2) the inability of skin scrub-
bing prior to disinfection to reduce catheter colonization
when the skin is not visibly soiled.
Methods
Ethics statement
The study was approved by the local ethics committee
(CPP Ouest III, France) on 21 May 2012 (Protocol#
12.02.06). Each patient will have oral and written infor-
mation concerning the study design and outcomes. If
the information cannot be delivered to the patient, it will
be delivered to his/her relatives.
Study design
The CLEAN study is a prospective multicenter, 2×2
factorial, randomized-controlled, assessor-blind trial in-
volving 11 intensive care units in five French University-
affiliated hospitals and one French general hospital and
is designed to compare two antiseptics (2% chlorhexi-
dine/70% isopropyl alcohol and 5% povidone iodine/69%
ethanol) with or without prior skin scrubbing. Due to
the different colors of the two solutions, nurses and phy-
sicians will not be blinded to the antiseptic agent used.However, the microbiologists assigned to process all of
the cultures and the adjudication committee tasked with
reviewing the outcomes other than colonization will be
unaware of the patients’ arms.
Inclusions opened at the end of October 2012 and will
close approximately 14 months later.
Patients
All consecutive adult patients aged over 18 years, hospi-
talized in one of participating ICUs for an expected
length of stay of >2 days and requiring insertion of at
least one peripheral arterial catheter and/or a non-
tunneled central venous catheter and/or a hemodialysis
catheter and/or an arterial pulmonary catheter will be
included in the trial. Exclusion criteria will be catheters
inserted outside the ICUs, patients with a history of
allergy to any of the antiseptic agents studied, patients
likely to die within 48 h after admission, and use of cath-
eters coated with antimicrobial agents.
Randomization
Patients will be randomly assigned in a 1:1:1:1 ratio to have
all their catheters cared with either 2% chlorhexidine/70%
isopropyl alcohol (Chloraprep™, CareFusion™, Voisins le
Bretonneux, France) or 5% povidone iodine/69% ethanol
(alcohol Bétadine™, MEDA™ Pharma SAS, Paris, France)
with or without prior scrubbing with an antiseptic scrub.
Randomization will be stratified by hospital with the
use of a web-based random-number generator producing
permuted blocks to address for potential interhospital
heterogeneity.
Skin antisepsis
Antiseptic agents used will be:
– 5% povidone iodine/69% ethanol preceded or not by
scrubbing insertion site with a detergent (4%
povidone iodine, Betadine™ Scrub, MEDA™ Pharma).
– 2% chlorhexidine/70% isopropyl alcohol (applicator
sponge soaked with the antiseptic, Chloraprep™)
preceded or not by scrubbing insertion site with a
detergent (4% chlorhexidine, Hibiscrub™, Molnlycke
Health Care, Wasquehal, France).
According to the randomization arm, antiseptic strat-
egy during catheter insertion and maintenance will be:
– One-step procedure. The physician who will insert
the catheter will disinfect the skin using maximal
barrier precautions (surgical hand antisepsis and
wearing a gown, cap, mask, and sterile gloves).
Antiseptic will be applied moving back and forth
(2% chlorhexidine/70% isopropyl alcohol) or by
circular movements (5% povidone iodine/69%
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site and then expanding to the entire work area.
Large sterile drapes will be applied once the work
area dries. Catheters will then be inserted without
any further application of antiseptic.
– Four-step procedure. The work area will be
scrubbed by a nurse using sterile gauze soaked with
detergent applied by circular movements for 15 s,
rinsed with sterile water, and dried with sterile
gauze. Antiseptic and large sterile drapes will then
be applied by the physician using maximal barrier
precautions as described in the one-step procedure.
Finally, catheters will be inserted without any
further application of antiseptic.
In order to avoid any risk of confusion, antiseptic kits
containing all the products needed according to rando-
mization arm will be available in the patient’s room; simi-
larly, a poster showing how to carry out skin preparation
will be displayed in the patient's room. Training for
healthcare providers designed to homogenize skin prepar-
ation practices between units will be held before starting
inclusions. A clinical research associate will be available at
each participating Hospital to help with data collection
and to monitor for adequate practices.
Catheter insertion and maintenance
All study centers are to follow French recommendations
(similar to those of the CDC) for catheter insertion and
care. Use of the subclavian vein (except for hemodialysis
catheter) and radial artery will be encouraged whenever
possible. Catheters will be placed percutaneously using
the Seldinger technique. Ultrasound guidance shall be
used at the discretion of the attending physician. Before
catheter insertion, the skin will be disinfected with the
randomized antiseptic procedure assignment. After in-
sertion, catheters will be dressed with semi-permeable
non-chlorhexidine transparent dressing. For each unit,
the same catheter and dressing types will be used for the
duration of the study period. Catheter insertion sites will
be inspected every day for signs of infection. Dressing
will be changed every 72 h to 7 days according to center
protocol or earlier if leaking, soiled, or wet (except for the
first dressing changed 24 h after catheter insertion). Ma-
nipulation of lines and three-way stopcocks will be carried
out with gauze moistened with 5% povidone iodine/69%
ethanol in povidone iodine arms and 0.5% chlorhexidine/
67% alcohol (Hibitane Champ™, Molnlycke Health Care,
Wasquehal, France) in the chlorhexidine arm.
Use of antiseptic-containing dressings, topical anti-
microbial ointments, antimicrobial filters, and line locks
will not be allowed. Blood sampling through the central
venous line will not be permitted. The decision to re-
move the catheter will be made solely by the patient’sphysician, but ablation of the catheter when it is losing
its usefulness will be encouraged. Patients leaving the
ICU with their central venous catheter will undergo one
peripheral and one central line blood culture and will be
followed for 3 days after ICU discharge to monitor pos-
sible infectious complications. Any catheter infection oc-
curring >3 days after ICU discharge will not be taken
into account due to the risk of protocol violation during
catheter manipulation or of maintenance by untrained
healthcare providers.
Cultures
Catheters will be removed aseptically and their distal
5cm will be sectioned with sterile scissors and placed in
a sterile tube before being carried to the microbiology
laboratory. Catheters will be cultured quantitatively by
using a simplified technique of quantitative broth dilu-
tion culture [1,14].
Sets of aerobic and anaerobic blood cultures will be
routinely obtained when a patient has fever, hypother-
mia, or other indications such as chills or sudden shock.
Skin colonization will be evaluated before catheter re-
moval by using semi-quantitative insertion-site cultures.
The insertion site will be sampled by pressing on the
skin for 10 s a sterilized nutritive trypticase-soy agar
plate containing antiseptic neutralizing agents (Count-
tact™, 3P Pack+, Biomerieux™, Crapone, France).The
plate will then be sent to the local microbiology labora-
tory and cultured for 48 h. The number of colony-
forming units will be counted and classified as: sterile; 1
to 9 CFU; 10 to 49 CFU, 50 to 99 CFU, or ≥100 CFU
per agar plate as previously done [9,15].
All cultures will be processed by the clinical microbiol-
ogy laboratory according to standard methods without
awareness of the randomization arm.
In cases of suspected catheter-related infection (that
is, all the catheters removed with systemic inflammatory
response syndrome (SIRS) or local signs of infection
(pain or purulence) or positive catheter tip culture, or
positive blood culture sampled 48 h before until 48 h
after the catheter removal), the patient’s form will be
reviewed by an independent adjudication committee. In
the event of doubt, a complete blind patient record will
be prepared by the clinical research associates. Two in-
dependent experts blinded to the randomization arm
will classify these episodes according to infection defini-
tions (see below). In case of disagreement, the opinion
of a third expert will be sought.
Data collection
– For each center: number of hospital beds, type of
ICU (medical, surgical or mixed, number of ICU
beds, number of admissions a year in ICU, mean
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mean length of stay in ICU, and details of
procedures for catheter insertion and maintenance.
– For each patient included: demographic data (age,
sex, weight, and height), SAPS II and Sequential
Organ Failure Assessment (SOFA) [1] scores at
admission, length of mechanical ventilation, use of
catecholamines, clinical and microbiological data
needed to confirm the diagnostic of catheter-related
infection.
– For each catheter: catheter insertion date, insertion
site, catheter removal date, use of ultrasound
guidance, insertion using guidewire exchange,
experience of the operator, IGS II and SOFA scores
at catheter insertion, antibiotics at catheter
insertion, antibiotics used during catheter stay,
administration of parenteral nutrition, propofol or
blood product administration, reason(s) for catheter
withdrawal, catheter tip culture result, blood culture
result, local signs at catheter insertion site, status of
dressing at catheter removal, evolution of signs of
infection at catheter withdrawal, number and results
of blood cultures drawn within 48 h around catheter
removal during catheter stay, and skin colonization
at removal of catheter assessed using semi-
quantitative insertion site culture.
Three audits will be conducted in each center, each of
them including four catheter insertions and 10 dressing
changes, the first one during the first 2 months of study,
the second one after inclusion of 100 patients, and the
last one after inclusion of 200 patients. The costs of each
antiseptic strategy will be evaluated based on material
and time needed for skin preparation.
Definitions
French [9] and American [7] guidelines will be used by
the blind adjudication committee.
– Catheter colonization will be defined as a
quantitative culture tip showing at least one micro-
organism at a concentration of 1,000 colonies
forming 1 unit per milliliter (cfu/mL) or more.
– Catheter-related sepsis without bacteremia will be
defined according to the combination of (1) fever
(body temperature ≥38.5°C) or hypothermia body
temperature ≤36.5°C), (2) catheter colonization, (3)
regression of fever or hypothermia within the 48 h
following catheter removal and without any change
of antimicrobial therapy, or presence of pus at
catheter insertion site, and (4) no other source of
infection identified.
– Catheter-related bloodstream infection will be
defined as the combination of (1) fever (bodytemperature ≥38.5°C) or hypothermia body
temperature ≤36.5°C), (2) one or more positive
peripheral blood cultures drawn 48 h before or after
catheter withdrawal, (3) isolation of the same
organism (same species and same susceptibility
pattern) from the colonized catheter, or from the
catheter insertion site, or a blood-culture differential
time-to-positivity of 2 h or more, and (4) no
apparent source of bacteremia other than the
catheter. In patients with positive coagulase negative
staphylococci bacteremia, at least two positive
cultures obtained from separate blood samples will
be mandatory.
– Major catheter-related infections will be either
catheter-related sepsis without bacteremia or
catheter-related bloodstream infections.
– Non-cultured catheters or catheters growing under
1,000 cfu/mL will be classified as catheter-related sepsis
or bloodstream infections in case of sepsis without or
with bacteremia and no other detectable source.
– Non-cultured catheters will be classified as not
colonized unless there was sepsis with no other
detectable cause.Outcomes
The main endpoint will be to demonstrate that com-
pared to 5% povidone iodine/69% ethanol, use of 2%
chlorhexidine/70% isopropyl alcohol for skin preparation
lowers the rate of major catheter-related infection. The
second endpoint will be to demonstrate that skin scrub-
bing prior to antiseptic application does not reduce
catheter colonization when the skin is not visibly soiled.
Other outcomes include comparison of colonization at
catheter insertion site, catheter colonization, and
catheter-related bacteremia, as well as cutaneous toler-
ance, length of hospitalization, mortality, and costs
between the four strategies of preparation of skin. In
particular, a comparison between 2% chlorhexidine/70%
isopropyl alcohol not preceded by scrubbing and 5%
povidone iodine/69% ethanol preceded by scrubbing will
be carried out.Assessment endpoints
Density incidence of major catheter-related infection,
catheter colonization, catheter-related bloodstream in-
fection, and skin colonization at catheter insertion site
for all catheters and for arterial or central venous cathe-
ters only; mortality rate in ICU and in the hospital;
length of stay in ICU and in hospital; incidence of cuta-
neous allergy using the International Contact Dermatitis
Research Group scale [17]; cost of each strategy of skin
preparation.
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Assuming 5% of catheter-related infection rate in the 5%
povidone iodine/69% ethanol group (that is, incidence
density of 4 per 1,000 catheters days) and the use of at
least two catheters per patient on average, 453 patients
in each treatment arm will be required to demonstrate a
50% reduction of major catheter-related infection with
the use of 2% chlorhexidine/70% isopropyl alcohol, with
a power of 80% and a two-sided alpha risk of 5%. We
plan to enroll 2,400 patients (4,800 catheters) to take
into account the interaction between antiseptic efficacy
and skin scrubbing and a maximum patient loss of 6%.Statistical analysis
The data will be analyzed blindly with regard to treat-
ment arms. An intention-to-treat analysis is scheduled,
and it will include all patients except those with no cath-
eter inserted and those who will have withdrawn their
consent to participate in the study. No interim analyses
are planned. Demographic data will be described in
number and percentage or median and interquartile
range for quantitative and qualitative variables and com-
pared with χ2 test or Mann–Whitney, as appropriate.
Kaplan-Meir curves of the risks of major-CRI and CR-
BSI and catheter colonization will be plotted for each
treatment group. Proportional hazard assumption will be
assessed by plotting Schoenfield’s residuals with time.
Analysis of antiseptic efficacy will be carried out using
a marginal Cox model stratified by centers [18]. This
model takes into account the censored nature of the
data and also accounts for intra-cluster (intra-patient)
dependence (more than one catheter per patient) using a
robust sandwich covariance matrix. The interaction be-
tween scrubbing and antiseptic effect will be sought first
by forcing the interaction term in the final model. In the
absence of interaction, analysis of skin scrubbing and
chlorhexidine effects will be performed independently.
For secondary endpoints the analyses will not be con-
trolled for multiple testing.
Comparisons of skin cultures between groups will be
assessed through multiple factor ANOVA (Center,
scrubbing, antiseptic).
Analyses will be done using SAS 9.x (SAS Institute,
Cary, NC,USA) and R (R foundation, Vienna, Austria)
softwares.Length of patient follow-up
Patients will be followed up for the duration of their stay
in ICU. Insofar as possible the catheter will be removed
before patients’ discharge from ICU. If not, one peripheral
and one through-the-line blood culture will be drawn at
discharge and a visit at day 3 will take place in order to en-
quire about the diagnostic of catheter-related infection.End of participation in the study
A patient will leave the study if he (she) refuses to par-
ticipate to it, if an exclusion criterion appears during
hospital stay, if a severe adverse event occurs or if there
is an allergy to one of the antiseptic agents.
Discussion
This study will help to update recommendations on how
to prepare the skin prior to insertion of a vascular cath-
eter and, by extension, an epidural catheter, of which it
is estimated that approximately 30 million are inserted
every year in France. Although chlorhexidine is consid-
ered the most effective antiseptic in reducing catheter-
related infections, its superiority over alcoholic povidone
iodine is based on only a few studies, which have not in-
cluded enough patients to demonstrate any significant
effect on infection. A study adequately powered to dem-
onstrate the superiority of chlorhexidine over alcoholic
povidone iodine in reducing major catheter-related
infections is warranted (7). Skin scrubbing is rapid
(<2 min) and inexpensive (<€1), but since it is performed
several million times a year by nurses in French hospi-
tals, it leads to substantial costs.
Study limitations. The possible impact on the findings of
different types and concentrations of alcohol contained in
both antiseptics studied, of different methods of applica-
tion of antiseptics and of different antiseptics used for ma-
nipulating the lines and of three-way taps shall not be
assessed. However, antiseptics will be used in their avail-
able formulations and in accordance with the manufac-
turers’ recommendations.
Trial status
The trial is currently including patients. The inclusion
process started on 26 October 2012 and the number of
patients included is 691. The estimated length of inclu-
sion time is 15 months.
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